The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Quadramet     hydrogen(+1) cation; samarium(+3) cation;...

Synonyms: Sm-Edtmp, Quadramet (TN), LS-172536, AC1L4U95, D08504, ...
This record was replaced with 15025.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NSC18477


Psychiatry related information on NSC18477

  • Even this approximate dosimetric approach, considering the individual differences in tumour spread and the varying intensity of 153Sm uptake, could improve the impact of 153Sm-EDTMP for pain control in cancer patients [6].

High impact information on NSC18477


Chemical compound and disease context of NSC18477


Biological context of NSC18477


Anatomical context of NSC18477

  • A study was undertaken to determine the degree of acute bone marrow and vital organs injury sustained when dogs were administered doses of 153Sm-EDTMP calculated to irradiate an acute bone lesion arising from cancer metastasis to a dose considered palliative or even therapeutic (20-160 Gy) [15].
  • The purpose of this study was to evaluate the degree of cytological radiation damage to peripheral blood lymphocytes induced by 153Sm-EDTMP applied for palliation of metastatic bone pain [16].
  • A transient drop in white blood cell count and platelet count was observed following each 153Sm-EDTMP treatment [17].
  • This method was applied in a comparison of the uptake patterns of 153Sm-EDTMP and 89SrCl2 in sections obtained from a dog with spontaneous osteosarcoma, containing both tumour and normal bone tissues [18].

Gene context of NSC18477


Analytical, diagnostic and therapeutic context of NSC18477


  1. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation. Turner, J.H., Claringbold, P.G., Manning, L.S., O'Donoghue, H.L., Berger, J.D., Glancy, R.J. J. Natl. Cancer Inst. (1993) [Pubmed]
  2. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. Serafini, A.N., Houston, S.J., Resche, I., Quick, D.P., Grund, F.M., Ell, P.J., Bertrand, A., Ahmann, F.R., Orihuela, E., Reid, R.H., Lerski, R.A., Collier, B.D., McKillop, J.H., Purnell, G.L., Pecking, A.P., Thomas, F.D., Harrison, K.A. J. Clin. Oncol. (1998) [Pubmed]
  3. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Anderson, P.M., Wiseman, G.A., Erlandson, L., Rodriguez, V., Trotz, B., Dubansky, S.A., Albritton, K. Clin. Cancer Res. (2005) [Pubmed]
  4. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Alberts, A.S., Smit, B.J., Louw, W.K., van Rensburg, A.J., van Beek, A., Kritzinger, V., Nel, J.S. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. (1997) [Pubmed]
  5. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. Liepe, K., Runge, R., Kotzerke, J. J. Cancer Res. Clin. Oncol. (2005) [Pubmed]
  6. An individual dosimetric approach to 153Sm-EDTMP therapy for pain palliation in bone metastases in correlation with clinical results. Kendler, D., Donnemiller, E., Oberladstätter, M., Erler, H., Gabriel, M., Riccabona, G. Nuclear medicine communications. (2004) [Pubmed]
  7. Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen. Kennedy, G.A., Durrant, S., Butler, J., Morton, J., Western, R., Bartlett, M.L., Allison, R., MacFarlane, D.J. Leukemia (2005) [Pubmed]
  8. Intraorgan biodistribution and dosimetry of 153Sm-ethylenediaminetetramethylene phosphonate in juvenile rabbit tibia: implications for targeted radiotherapy of osteosarcoma. Essman, S.C., Lewis, M.R., Miller, W.H. J. Nucl. Med. (2005) [Pubmed]
  9. Samarium-153-EDTMP for palliation of ankylosing spondylitis, Paget's disease and rheumatoid arthritis. Alberts, A.S., Brighton, S.W., Kempff, P., Louw, W.K., Beek, A.V., Kritzinger, V., Westerink, H.P., van Rensburg, A.J. J. Nucl. Med. (1995) [Pubmed]
  10. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. Turner, J.H., Claringbold, P.G., Hetherington, E.L., Sorby, P., Martindale, A.A. J. Clin. Oncol. (1989) [Pubmed]
  11. Samarium for osteoblastic bone metastases and osteosarcoma. Anderson, P. Expert opinion on pharmacotherapy. (2006) [Pubmed]
  12. Comparative in vivo and in vitro study of the cytogenetic effects of 153Sm-EDTMP in lymphocytes of patients with bone metastases. da Silva, M.A., Suzuki, M.F., Guimarães, M.I., Buchpiguel, C.A., Rogero, J.R., Yoriyaz, H., Siqueira, P.T., Coelho, P.R., Okazaki, K. Cell. Mol. Biol. (Noisy-le-grand) (2002) [Pubmed]
  13. 153Sm-EDTMP radionuclide treatment of bony metastatic disease: a radiation protection evaluation. Moro, L., Fantinato, D., Aprile, C., Preti, P., Robustelli della Cuna, G. Giornale italiano di medicina del lavoro ed ergonomia. (2001) [Pubmed]
  14. Pharmacokinetics of samarium-153-EDTMP in disseminated skeletal metastases. Pusuwan, P., Chaiwatanarat, T., Chaudakshetrin, P., Virawat, N., Pattaranutaporn, P., Chansilpa, Y., Suntornpong, N., Tocharoenchai, C., Buranapong, P., Chanachai, R., Suputtamongkol, Y., Pleehachinda, R. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. (1996) [Pubmed]
  15. Clinical and clinicopathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogs. Lattimer, J.C., Corwin, L.A., Stapleton, J., Volkert, W.A., Ehrhardt, G.J., Ketring, A.R., Hewett, J.E., Simon, J., Goeckeler, W.F. J. Nucl. Med. (1990) [Pubmed]
  16. Induction of micronuclei by 153Sm-EDTMP in peripheral blood lymphocytes of patients with bone metastases. Suzuki, M.F., Silva, M.A., Murakami, D., Guimaraes, M.I., Okazaki, K. Cell. Mol. Biol. (Noisy-le-grand) (2002) [Pubmed]
  17. Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma. Moe, L., Boysen, M., Aas, M., Lønaas, L., Gamlem, H., Bruland, O.S. The Journal of small animal practice. (1996) [Pubmed]
  18. A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section with a digital silicon detector: application to a study of 89SrCl2 and 153Sm-EDTMP in a dog with spontaneous osteosarcoma. Kvinnsland, Y., Bruland, O., Moe, L., Skretting, A. Eur. J. Nucl. Med. Mol. Imaging (2002) [Pubmed]
  19. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP. van Rensburg, A.J., Alberts, A.S., Louw, W.K. J. Nucl. Med. (1998) [Pubmed]
  20. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy. Cameron, P.J., Klemp, P.F., Martindale, A.A., Turner, J.H. Nuclear medicine communications. (1999) [Pubmed]
  21. Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. Bruland, O.S., Skretting, A., Solheim, O.P., Aas, M. Acta oncologica (Stockholm, Sweden) (1996) [Pubmed]
WikiGenes - Universities